Dr. Jahanzeb on the Benefit of Pertuzumab Plus Trastuzumab in HER2+ Breast Cancer

Dr. Jahanzeb Discusses Advancements in Adjuvant HER2+ Breast CancerПодробнее

Dr. Jahanzeb on the APHINITY and ExteNET Trials in Breast CancerПодробнее

Trastuzumab deruxtecan shows benefit in patients with HER2 + mBCПодробнее

Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HE...Подробнее

Dr. Jahanzeb on Overcoming HER2 Resistance in Breast CancerПодробнее

Dr. Pegram on Pertuzumab Plus Trastuzumab and Chemotherapy in Breast CancerПодробнее

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast c...Подробнее

Dr. Mohammad Jahanzeb on Neratinib and Trastuzumab in HER2-Positive Breast CancerПодробнее

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-posi...Подробнее

Dr. Yee on Neoadjuvant Pertuzumab in HER2-Positive Breast CancerПодробнее

Dr. Osborne on Pertuzumab in HER2+ Breast CancerПодробнее

Trastuzumab (Herceptin) and Pertuzumab (Perjeta) for Breast Cancer: What You Need to KnowПодробнее

Dr. Pegram Discusses Adjuvant Pertuzumab in HER2+ Breast CancerПодробнее

Study of Atezolizumab with Pertuzumab and Trastuzumab in HER2- Positive Metastatic Breast CancerПодробнее

PRECIOUS: pertuzumab retreatment in patients with HER+ breast cancerПодробнее

Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancerПодробнее

Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast CancerПодробнее

Dr. Mittendorf on the Impact of Pertuzumab in HER2+ Breast CancerПодробнее

Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroupsПодробнее